Success Story: NIW Approved Without RFE! Our Firm Helped a Graduate Student Secure Success
Client’s Testimonial:
"Working with this firm was an exceptional experience from start to finish. The team meticulously structured my petition, effectively highlighting the significance and practical application of my research to secure approval without an RFE. Their responsiveness, depth of knowledge, and efficiency exceeded my expectations. I strongly recommend their legal team to fellow researchers and graduate students."
On August 18th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Student in the Field of Biochemistry (Approval Notice).
General Field: Biochemistry
Position at the Time of Case Filing: Graduate Student
Country of Origin: South Korea
Country of Residence at the Time of Filing: New York
Approval Notice Date: August 18th, 2026
Processing Time: 2 months, 20 days (Premium Processing Upgrade Requested)
Case Summary:
Developing more precise treatments for complex diseases requires researchers to identify biological targets that can distinguish disease processes more effectively and support more selective therapeutic strategies. Working at this intersection of biochemistry and therapeutic development, our client sought an I-140 EB-2 National Interest Waiver (NIW) to continue research aimed at developing advanced antibody-based approaches for cancer and autoimmune disorders. The client holds an M.Phil. in chemistry and is currently conducting research at a U.S. university.
Rather than focusing on the highly specialized technical details of the client's research, we demonstrated how the proposed endeavor could contribute to broader U.S. needs. The client's work seeks to improve the design and targeting of biological therapies so that disease-associated features can be identified and addressed with greater precision. We connected these research plans to challenges in cancer treatment, public health, healthcare costs, and continued U.S. leadership in health and biotechnology research.
A Research Record Supporting Future Progress
The client's academic record provided several objective indicators of sustained research activity:
- 5 peer-reviewed journal articles, including 1 first-authored article
- 1 first-authored abstract
- 42 citations to the client's published research
Research supported by major funding sources, including the National Science Foundation and National Institutes of Health
These figures were not presented as stand-alone proof of significance. Instead, we placed them in context to show how the client's work had developed a record of recognition and use within the field. In particular, two of the client's articles ranked among the top 20% most-cited papers in their respective field and publication years. This comparison helped demonstrate that the citation record reflected meaningful scholarly attention when evaluated relative to comparable research.
We also documented specific instances in which independent researchers relied on the client's prior findings and methods to support their own investigations. Such downstream use provided stronger evidence of influence than citation numbers alone because it showed that other researchers were building upon the client's contributions in areas related to biochemical methods, molecular processes, and therapeutic research.
The NIW case ultimately brought these different forms of evidence together. We highlighted the client's specialized education and research experience, publication and citation record, independent reliance on the client's work, federal research support, and concrete plans for continued research. We further demonstrated how the proposed work could advance more precise approaches to treating serious diseases while contributing to broader U.S. public health and biotechnology priorities.
The client's I-140 NIW petition was approved. We are pleased that the client can continue pursuing research in biochemistry with the potential to strengthen precision therapeutic development and contribute to future advances in disease treatment in the United States.